Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

  • Showing results for a modified search because your search retrieved no results.

Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents.

Zhang X, Haney KM, Richardson AC, Wilson E, Gewirtz DA, Ware JL, Zehner ZE, Zhang Y.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4627-30. doi: 10.1016/j.bmcl.2010.06.003. Epub 2010 Jun 8.


Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Zhang F, Arnatt CK, Haney KM, Fang HC, Bajacan JE, Richardson AC, Ware JL, Zhang Y.

Eur J Med Chem. 2012 Sep;55:395-408. doi: 10.1016/j.ejmech.2012.07.049. Epub 2012 Aug 7.


The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.

Haney KM, Zhang F, Arnatt CK, Yuan Y, Li G, Ware JL, Gewirtz DA, Zhang Y.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5159-63. doi: 10.1016/j.bmcl.2011.07.058. Epub 2011 Jul 23.


The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.

Zhang Y, Arnatt CK, Zhang F, Wang J, Haney KM, Fang X.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5093-7. doi: 10.1016/j.bmcl.2012.05.127. Epub 2012 Jun 16.


Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents.

Arnatt CK, Zaidi SA, Zhang Z, Li G, Richardson AC, Ware JL, Zhang Y.

Eur J Med Chem. 2013 Nov;69:647-58. doi: 10.1016/j.ejmech.2013.09.004. Epub 2013 Sep 20.


Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.

Li G, Haney KM, Kellogg GE, Zhang Y.

J Chem Inf Model. 2009 Jan;49(1):120-32. doi: 10.1021/ci800356a.


Total synthesis of anibamine, a novel natural product as a chemokine receptor CCR5 antagonist.

Li G, Watson K, Buckheit RW, Zhang Y.

Org Lett. 2007 May 10;9(10):2043-6. Epub 2007 Apr 21.


Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.

Arnatt CK, Adams JL, Zhang Z, Haney KM, Li G, Zhang Y.

Bioorg Med Chem Lett. 2014 May 15;24(10):2319-23. doi: 10.1016/j.bmcl.2014.03.073. Epub 2014 Apr 3.


Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.

Xu GG, Zaidi SA, Zhang F, Singh S, Raborg TJ, Yuan Y, Zhang Y.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3721-5. doi: 10.1016/j.bmcl.2015.06.029. Epub 2015 Jun 15.


Expression of CCL5 (RANTES) and CCR5 in prostate cancer.

Vaday GG, Peehl DM, Kadam PA, Lawrence DM.

Prostate. 2006 Feb 1;66(2):124-34.


CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.


Isolation and structure of antagonists of chemokine receptor (CCR5).

Jayasuriya H, Herath KB, Ondeyka JG, Polishook JD, Bills GF, Dombrowski AW, Springer MS, Siciliano S, Malkowitz L, Sanchez M, Guan Z, Tiwari S, Stevenson DW, Borris RP, Singh SB.

J Nat Prod. 2004 Jun;67(6):1036-8.


CCR5 antagonist blocks metastasis of basal breast cancer cells.

Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG.

Cancer Res. 2012 Aug 1;72(15):3839-50. doi: 10.1158/0008-5472.CAN-11-3917. Epub 2012 May 25.


Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.

Zhang F, Zaidi S, Haney KM, Kellogg GE, Zhang Y.

J Org Chem. 2011 Oct 7;76(19):7945-52. doi: 10.1021/jo2013669. Epub 2011 Sep 13.


Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.

Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.

Prostate. 1997 Aug 1;32(3):164-72.


High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O.

Clin Cancer Res. 2009 Oct 1;15(19):6070-8. doi: 10.1158/1078-0432.CCR-09-1035. Epub 2009 Sep 29.


I-TAC/CXCL11 is a natural antagonist for CCR5.

Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.

J Leukoc Biol. 2004 Sep;76(3):701-8. Epub 2004 Jun 3.


Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice.

Ni F, Gong Y, Li L, Abdolmaleky HM, Zhou JR.

PLoS One. 2012;7(6):e38802. doi: 10.1371/journal.pone.0038802. Epub 2012 Jun 5.


The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.

Shen Z, Li T, Chen D, Jia S, Yang X, Liang L, Chai J, Cheng X, Yang X, Sun M.

Oncol Rep. 2014 Feb;31(2):800-6. doi: 10.3892/or.2013.2920. Epub 2013 Dec 13.


SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM.

Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12718-23. Epub 2001 Oct 16.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk